Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life
Dermatology · 2023
DOI: 10.1159/000531708 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology, 2023. Verfasst von Clara Richter und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Prurigo, Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chronic prurigo (CPG) is a pruritic skin disease, characterized by an itch-scratch cycle and scarring. It reduces patients’ quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through blockade of the IL-4 receptor. Patients with CPG who receive dupilumab often report great improvement in itch and overall QoL. We therefore reviewed our experience in order to follow up on QoL, safety, and treatment response in patients with CPG who received dupilumab.
Methods
We conducted a real-world retrospective single-center case series. Outcomes were assessed by phone interviews and photographs using validated questionnaires and scores. Demographic data were obtained from the hospital files. Follow-up was up to 2 years. We assessed QoL with the Dermatology Life Quality Index (DLQI) and the Itchy quality of life questionnaire (ItchyQoL). Numerical Rating Scale (NRS) was used to assess itch. Prurigo lesions were documented with the Prurigo activity and severity score (PAS).
Results
Ten patients were included in this study. Results were reported up to 2 years after treatment with dupilumab. The response variables for DLQI, ItchyQoL, NRS, and PAS analyses showed a statistically significant decrease over time (DLQI: p ≤ 0.0001 [−0.84; −1.27], ItchyQoL: p ≤ 0.0001 [−9.89; −18.69], NRS maximum and average: p ≤ 0.0001 [−0.52; −0.86] and p ≤ 0.0001 [−0.55; −0.94], and PAS number of lesions: p = 0.0005 [−1.70; −5.28]). The percent decrease after 1 year of treatment (this estimate is based on model estimates) ranges from −42% to −82%. Four (40%) patients reported mild side effects. No serious side effects were reported.
Conclusion
Dupilumab treatment of CGP for up to 2 years is associated with improved QoL and less itching.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Zurich Data Scientists, Zurich, Switzerland.
- Christine Kühne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.
Zitieren
APA
Richter, C., Hafner, J., Schuermann, M., Tanadini, M., Trisconi, N., Schmid-Grendelmeier, P., Kündig, T., Nägeli, M., Brüggen, M. C., & Guillet, C. (2023). Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life. Dermatology. https://doi.org/10.1159/000531708
Vancouver
Richter C, Hafner J, Schuermann M, Tanadini M, Trisconi N, Schmid-Grendelmeier P, et al. Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life. Dermatology. 2023. doi:10.1159/000531708
BibTeX
@article{Richter2023,
author = {Richter, Clara and Hafner, Jürg and Schuermann, Manuel and Tanadini, Matteo and Trisconi, Nisia and Schmid-Grendelmeier, Peter and Kündig, Thomas and Nägeli, Mirjam and Brüggen, Marie-Charlotte and Guillet, Carole},
title = {Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life},
journal = {Dermatology},
year = {2023},
doi = {10.1159/000531708}
}
EUVIMED